The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

REVUE DES MALADIES RESPIRATOIRES is a distinguished journal published by MASSON EDITEUR, focusing on the vital field of pulmonary and respiratory medicine. Established in 1984, this journal has become a prominent platform for sharing innovative research and clinical findings, reflecting an impressive array of studies that contribute to our understanding of respiratory diseases. With its ISSN 0761-8425 and E-ISSN 1776-2588, it facilitates access to scholarly work within the medical community, although it currently operates under a subscription model rather than Open Access. As indicated by its quartile ranking of Q4 in 2023 within its category and a Scopus rank of #128/155, REVUE DES MALADIES RESPIRATOIRES serves as an essential resource for researchers, professionals, and students aiming to stay informed about advancements in respiratory health. This journal plays a crucial role in fostering discussions that drive innovation and best practices in the treatment and understanding of respiratory conditions.

Multidisciplinary Respiratory Medicine is a leading open-access journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by MATTIOLI 1885, this journal has been serving the academic community since 2008 and has become a vital platform for the dissemination of research and clinical insights in this critical area of healthcare. With an impressive impact factor placing it in the Q2 category of pulmonary medicine in 2023 and a Scopus rank of #67 out of 155, it reflects a solid commitment to high-quality research. The journal provides researchers, health professionals, and students with accessible and updated information, fostering collaboration and advancement in respiratory health. Operating from the United Kingdom, it has embraced open access since 2010, ensuring that all articles are freely available, thus maximizing the reach and impact of its scholarly contributions. Whether you are looking to publish innovative findings or gain insights from industry leaders, Multidisciplinary Respiratory Medicine is your go-to resource for the latest in respiratory science.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.

Minerva Respiratory Medicine is a prominent academic journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by EDIZIONI MINERVA MEDICA in Italy, this journal provides a vital platform for the dissemination of innovative research, clinical studies, and review articles that address the complexities of respiratory health. With an ISSN of 2784-8477 and an E-ISSN of 2724-6493, it serves as an open-access resource, allowing researchers, healthcare professionals, and students access to invaluable information without barriers. The journal is categorized in the fourth quartile of the 2023 rankings in the field of pulmonary and respiratory medicine, indicating its emerging role in the academic landscape. Despite its nascent status—converging from 2021 to 2024—Minerva Respiratory Medicine is committed to enhancing knowledge and practice in respiratory care, focusing on both innovative therapies and traditional approaches. With its aim to foster collaboration and communication among professionals in the field, this journal is an essential resource for those passionate about improving respiratory health outcomes.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.